Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.92
+4.9%
$0.82
$0.55
$2.22
$11.44M1.481.69 million shs28,995 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$2.43
-1.0%
$2.21
$1.76
$4.18
$10.75M-0.48367,935 shs16,036 shs
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
$0.20
-0.2%
$0.21
$0.16
$33.66
$9.02MN/A8.12 million shs333,193 shs
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
$0.57
+4.0%
$0.66
$0.45
$6.18
$2.00M2.192.38 million shs161,280 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+5.66%+10.10%+23.87%+27.64%-45.97%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-2.39%+4.26%+13.43%+13.95%-26.87%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
-2.20%-1.76%+8.67%-89.10%+20,049,900.00%
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
-4.72%-26.57%-4.75%-34.66%-80.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.92
+4.9%
$0.82
$0.55
$2.22
$11.44M1.481.69 million shs28,995 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$2.43
-1.0%
$2.21
$1.76
$4.18
$10.75M-0.48367,935 shs16,036 shs
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
$0.20
-0.2%
$0.21
$0.16
$33.66
$9.02MN/A8.12 million shs333,193 shs
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
$0.57
+4.0%
$0.66
$0.45
$6.18
$2.00M2.192.38 million shs161,280 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+5.66%+10.10%+23.87%+27.64%-45.97%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-2.39%+4.26%+13.43%+13.95%-26.87%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
-2.20%-1.76%+8.67%-89.10%+20,049,900.00%
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
-4.72%-26.57%-4.75%-34.66%-80.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.40
Hold$4.40376.19% Upside
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
2.00
Hold$10.00312.20% Upside
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
1.00
SellN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SCNI, APRE, KPRX, and LIMN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Initiated CoverageOutperform$5.00
4/27/2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
Reiterated RatingSell (E+)
4/21/2026
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
Reiterated RatingSell (E+)
4/20/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Reiterated RatingSell (E+)
3/31/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Reiterated RatingOutperform$7.00
3/31/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Lower Price TargetBuy$4.00 ➝ $1.20
3/27/2026
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
Reiterated RatingSell (E+)
2/16/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
UpgradeStrong SellHold
2/10/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Lower Price TargetOutperform$11.00 ➝ $7.00
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$290K39.45N/AN/A$1.52 per share0.61
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$16.02M0.67N/AN/A$4.38 per share0.55
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/AN/AN/AN/A($0.36) per shareN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
$1.31M1.52N/AN/A$0.78 per share0.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.60M-$1.98N/AN/AN/A-4,405.59%-96.33%-74.35%5/13/2026 (Estimated)
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$10.84M-$2.65N/AN/AN/AN/A-51.37%-36.09%5/8/2026 (Estimated)
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
-$10.21M-$0.15N/AN/AN/AN/AN/A-402.52%N/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
-$8.31M-$9.57N/AN/AN/AN/AN/AN/A7/7/2026 (Estimated)

Latest SCNI, APRE, KPRX, and LIMN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.22N/AN/AN/A$0.00 millionN/A
5/8/2026Q1 2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.71-$0.58+$0.13-$0.58$1.50 millionN/A
4/1/2026Q4 2025
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
N/A$3.80N/A$3.80N/A$0.27 million
3/31/2026Q4 2025
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A-$0.34N/A-$0.34N/AN/A
3/25/2026Q4 2025
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.70-$1.60-$0.90-$1.60$1.50 millionN/A
3/16/2026Q4 2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.38-$0.32+$0.06-$0.32N/A$0.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/AN/AN/AN/AN/A
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/AN/AN/AN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
5.63
5.63
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/A
5.99
5.99
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A
0.05
0.05
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
0.12
1.30
1.30

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
76.97%
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
58.41%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
712.38 million10.70 millionNo Data
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
104.43 million4.43 millionNot Optionable
Liminatus Pharma Inc. stock logo
LIMN
Liminatus Pharma
N/A44.88 millionN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
203.54 million1.38 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$0.92 +0.04 (+4.92%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Kiora Pharmaceuticals stock logo

Kiora Pharmaceuticals NASDAQ:KPRX

$2.43 -0.02 (-0.98%)
As of 10:59 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Liminatus Pharma stock logo

Liminatus Pharma NASDAQ:LIMN

$0.20 0.00 (-0.25%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Scinai Immunotherapeutics stock logo

Scinai Immunotherapeutics NASDAQ:SCNI

$0.56 +0.02 (+3.97%)
As of 11:06 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.